Onconetix, Inc. (NASDAQ:ONCO) Short Interest Update

Onconetix, Inc. (NASDAQ:ONCO) was the recipient of a significant increase in short interest in November. As of November 15th, there was short interest totalling 33,300 shares, an increase of 53.5% from the October 31st total of 21,700 shares. Approximately 1.0% of the shares of the company are short sold. Based on an average trading volume of 674,800 shares, the short-interest ratio is currently 0.0 days.

Onconetix Trading Up 4.2 %

Shares of NASDAQ:ONCO traded up $0.03 during trading on Friday, hitting $0.69. 940,428 shares of the company were exchanged, compared to its average volume of 318,680. The stock has a 50 day moving average of $3.35 and a 200 day moving average of $5.16. Onconetix has a 52-week low of $0.60 and a 52-week high of $21.40.

Onconetix (NASDAQ:ONCO) last issued its quarterly earnings data on Thursday, August 29th. The company reported ($9.20) earnings per share (EPS) for the quarter. The company had revenue of $0.71 million during the quarter.

Institutional Investors Weigh In On Onconetix

A hedge fund recently bought a new stake in Onconetix stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Onconetix, Inc. (NASDAQ:ONCO) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 306,079 shares of the company’s stock, valued at approximately $51,000. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 1.37% of Onconetix as of its most recent filing with the Securities & Exchange Commission. 23.89% of the stock is currently owned by hedge funds and other institutional investors.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.